NCT07196722ClinicalTrials.gov

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

RecruitingTaking participants now, according to the registry record.

Contact this study

In brief

The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract).

Phase 2 / Phase 31,092 participants sought370 sites28 countries

Registered in 1 registry

ClinicalTrials.govNCT07196722Open this record at ClinicalTrials.govSynced 3 weeks ago

One study can be registered in several registries. We show it once and link every record we hold.

Trial information is shown as published by the registry, in its original language.

Interested in this study?

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

Present: Registered before enrolment beganFirst posted 2025-09-29; recorded start 2025-10-03
Present: Has a defined primary outcomeA primary outcome measure is listed in the record
Present: The primary outcome states a time frameThe primary outcome measure records a time frame
Present: Participants are randomly assignedAllocation is recorded as randomised
Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
Present: Uses blinding (masking)A masking level is recorded in the record
Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
Present: Sponsor has 228 other studies in this databaseCounted from the lead sponsor named in the record (Janssen Research & Development, LLC)
Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database

The record lists 1 condition.
Lead sponsor type recorded as: industry.
Intervention regulatory context: investigational, within a phased regulatory pathway.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built

Randomised allocation20/20
Participants are randomly allocated between arms
Blinding13/20
Double-blind
Control arm13/15
Placebo / sham control arm
Primary-outcome specificity10/10
Named primary outcome with a defined time frame
Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
Multi-centre8/8
Multi-centre: 367 sites
Data monitoring committee7/7
A data monitoring committee is in place
Prospective registration5/5
Registered before the study start date
Protocol / SAP posted0/5
No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 1,092 participants (target), run at 370 sites, across 28 countries.

How this score is built

Enrolment30/40
1,092 participants (target)
Site count25/25
367 sites
Country count15/15
28 countries
Planned duration10/10
Planned over about 85 months
Sponsor scale9/10
Janssen Research & Development, LLC has led 226 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built

Investigator standing0/100
No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Summary

Conditions

Crohn Disease

Eligibility

Eligibility
Sex	All
Ages	18 Years – No maximum
Healthy volunteers	No

Eligibility as written in the registry

Inclusion Criteria: * Diagnosis of CD established at least 12 weeks before screening including both endoscopic evidence and a histopathology report consistent with a diagnosis of CD * Moderately to severely active CD based on CDAI criteria, defined as baseline (Week I-0) CDAI score \>=220 but \<=450 and either mean daily SF count \>=4, or mean daily AP score \>=2 * Moderately to severely active CD based on SES-CD criteria assessed by baseline (Week I-0) endoscopic evidence of active ileal and/or colonic CD as assessed during central review of the screening video ileocolonoscopy defined as a SES-CD \>= 6 for participants with colonic or ileocolonic disease, and SES-CD \>= 4 for participants with isolated ileal disease, based on the presence of ulceration in any 1 of the 5 ileocolonic segments * A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (beta-hCG) at screening and a negative urine pregnancy test at Week I-0 prior to administration of study intervention and agree to further pregnancy tests * Demonstrated an inadequate response to, or failure to tolerate conventional therapy but naïve to advanced therapies (advanced drug therapy \[ADT\]-naïve) or inadequate response to (that is, primary or secondary nonresponse) or failure to tolerate advanced therapy defined as biologics and/or advanced oral agents for the treatment of CD- (ADT-inadequate responder \[IR\]) as defined in the protocol Exclusion criteria: * Has complications of CD, such as symptomatic strictures or stenoses, short gut syndrome, or any other manifestation, that may require surgery while enrolled in the study and/or could impair the use of instruments (such as CDAI) to assess response to study intervention * Presence of a stoma or ostomy * Participants with presence of active fistulas may be included if there is no surgery needed * Colonic resection within 24 weeks before baseline or any other major surgery performed within 12 weeks before baseline * Presence on screening colonoscopy of adenomatous colon polyps outside of an area of known colitis not removed before randomization

Eligibility in plain statements

This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.

Study design

Study design
Study type	Interventional
Phase	Phase 2 / Phase 3
Allocation	Randomised
Intervention model	PARALLEL
Primary purpose	TREATMENT
Masking	DOUBLE (2)
Enrolment	1,092 participants sought

Sponsor and collaborators

Janssen Research & Development, LLC Sponsor

Arms and interventions

Induction Study 1: Icotrokinra Dose 1EXPERIMENTAL
Participants will receive Icotrokinra dose 1 in Induction Study 1 up to Week 12. Subsequent treatment will be determined by the participant's response status at Week 12.
Induction Study 1: Icotrokinra Dose 2EXPERIMENTAL
Participants will receive Icotrokinra dose 2 in Induction Study 1 up to Week 12. Subsequent treatment will be determined by the participant's response status at Week 12.
Induction Study 1: PlaceboPLACEBO_COMPARATOR
Participants will receive matching placebo in Induction Study 1 up to Week 12. Subsequent treatment will be determined by the participant's response status at Week 12.
Induction Study 2: IcotrokinraEXPERIMENTAL
Participants will receive Icotrokinra at the dose regimen determined in Induction Study 1 up to Week 12. Subsequent study treatment will be determined by the participant's response status at Week 12.
Induction Study 2: PlaceboPLACEBO_COMPARATOR
Participants will receive matching placebo for up to Week 12. Subsequent study treatment will be determined by the participant's response status at Week 12.
Maintenance Study: Icotrokinra Dose 1EXPERIMENTAL
Participants who were receiving icotrokinra in either induction studies 1 or 2 and were in response at Week 12 of the induction study will be randomized to receive icotrokinra maintenance dose 1. Participants receiving Icotrokinra Dose 1 and meeting criteria for loss of response during the Maintenance Study will be eligibile for a single blinded dose adjustment to Icotrokinra Dose 2. After completion of the Maintenance Study through Week 40, eligible participants can participate in long-term extension (LTE).
Maintenance Study: Icotrokinra Dose 2EXPERIMENTAL
Participants who were receiving icotrokinra in either induction studies 1 or 2 and were in response at Week 12 of the induction study will be randomized to receive icotrokinra maintenance dose 2. Participants who were non-responders at Week 12 of the induction studies will also receive icotrokinra maintenance dose 2 but will not be randomized. After completion of the Maintenance Study through Week 40, eligible participants can participate in LTE.
Maintenance Study: PlaceboPLACEBO_COMPARATOR
Participants who were receiving icotrokinra in either induction studies 1 or 2 and were in response at Week 12 will be randomized to receive placebo. Participants receiving placebo in induction studies 1 or 2 and in response at Week 12 of the induction study will continue to receive placebo during maintenance on non-randomized basis. Placebo non-responders from induction study will receive icotrokinra maintenance dose 2 on a non-randomized basis and will be assessed for response at Week 12. Participants receiving placebo and meeting criteria for loss of response during the Maintenance Study will be eligible for a single blinded dose adjustment to icotrokinra dose 2. After completion of the Maintenance Study through Week 40, eligible participants can participate in LTE.

Interventions

Drug Icotrokinra
Icotrokinra will be administered orally, daily.
Drug Placebo
Matching placebo will be administered orally, daily.

Outcome measures

Primary outcome
Induction Study 1: Number of Participants with Clinical Response at Week 12
Clinical response is defined as a greater than or equal to (\>=) 100-point reduction from baseline in Crohn's Disease Activity Index (CDAI) score. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.
Time frame At Week 12
Primary outcome
Induction Study 2: Number of Participants with Clinical Remission at Week 12 (Co-Primary Endpoint)
Clinical remission is defined as CDAI score less than (\<) 150. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.
Time frame At Week 12
Primary outcome
Induction Study 2: Number of Participants with Endoscopic Response at Week 12 (Co-Primary Endpoint)
Endoscopic response is defined as greater than (\>) 50% improvement from baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) score or a decrease of at least 2 points in participants with a baseline score of 4 and isolated ileal disease. SES-CD score can range from 0 to 56. Higher scores indicating more severe disease.
Time frame At Week 12
Primary outcome
Maintenance Study: Number of Participants with Clinical Remission at Week 40 (Co-Primary Endpoint)
Clinical remission is defined as CDAI score \< 150. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.
Time frame At Week 40
Primary outcome
Maintenance Study: Number of Participants with Endoscopic Response at Week 40 (Co-Primary Endpoint)
Endoscopic response is defined as \> 50% improvement from baseline in SES-CD score or a decrease of at least 2 points in participants with a baseline score of 4 and isolated ileal disease. SES-CD score can range from 0 to 56. Higher scores indicating more severe disease.
Time frame At Week 40
Secondary outcome
Induction Study 1: Number of Participants with Clinical Remission at Week 12
Clinical remission is defined as CDAI score \< 150. CDAI scores ranging from 0 to approximately 600. Higher score indicates higher disease activity.
Time frame At Week 12
Secondary outcome
Induction Study 1: Number of Participants with Endoscopic Response at Week 12
Endoscopic response is defined as \> 50% improvement from baseline in SES-CD score or a decrease of at least 2 points in participants with a baseline score of 4 and isolated ileal disease. SES-CD score can range from 0 to 56. Higher scores indicating more severe disease.
Time frame At Week 12
Secondary outcome
Induction Study 1: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. An SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important.
Time frame Up to 4 weeks after last dose of study drug (i.e., up to Week 16)
Secondary outcome
Induction Study 2: Number of Participants with Patient Reported Outcomes (PRO)-2 Remission at Week 12
PRO-2 remission is defined as an abdominal pain (AP) mean daily score less than or equal to (\<=) 1 and stool frequency (SF) mean daily score \<= 2.8, and no worsening of AP or SF from baseline.
Time frame At Week 12
Secondary outcome
Induction Study 2: Number of Participants with Clinical Response at Week 12
Clinical response is defined as a \>= 100-point reduction from baseline in CDAI score.
Time frame At Week 12
Secondary outcome
Induction Study 2: Number of Participants Reporting Both Clinical Remission and Endoscopic Response at Week 12
Clinical remission is defined as CDAI score \< 150. Endoscopic response is defined as \> 50% improvement from baseline in SES-CD score or a decrease of at least 2 points in participants with a baseline score of 4 and isolated ileal disease. This is a composite endpoint defined to measure achievement of both clinical remission and endoscopic response at the participant level.
Time frame At Week 12
Secondary outcome
Induction Study 2: Number of Participants with Clinical Response at Week 4
Clinical response is defined as a \>= 100-point reduction from baseline in CDAI score.
Time frame At Week 4
Secondary outcome
Induction Study 2: Number of Participants with Endoscopic Remission at Week 12
Endoscopic remission is defined as SES-CD \<= 4 with at least a 2-point reduction from baseline and no sub score \>1 in any individual component.
Time frame At Week 12
Secondary outcome
Induction Study 2: Number of Participants with Deep Remission at Week 12
Deep remission is a composite endpoint defined as achieving both clinical remission and endoscopic remission at the participant level. Clinical remission is defined as CDAI score \< 150-point. Endoscopic remission is defined as SES-CD \<= 4 with at least a 2-point reduction from baseline and no sub score \>1 in any individual component.
Time frame At Week 12
Secondary outcome
Induction Study 2: Number of Participants with Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 12
IBDQ remission is defined as IBDQ score \>= 170. IBDQ is a validated, 32-item, self-reported questionnaire for participants with inflammatory bowel disease (IBD) that will be used to evaluate the disease-specific health-related quality of life (HRQoL) across 4 dimensional scores: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Scores range from 32 to 224, with higher scores indicating better outcomes.
Time frame At Week 12
Secondary outcome
Induction Study 2: Number of Participants with Fatigue Response at Week 12
Fatigue response is defined as a \>= 7 point reduction in the patient reported outcomes measurement information system (PROMIS)-Fatigue Short Form 7a total score from baseline. The PROMIS fatigue SF-7a contains 7 items evaluating fatigue-related symptoms (that is, tiredness, exhaustion, mental tiredness, and lack of energy) and associated impacts on daily activities (that is, activity limitations related to work, self-care, and exercise). Item responses are rated on a five-point scale ranging from "never" to "always". Higher scores indicate more fatigue.
Time frame At Week 12
Secondary outcome
Induction Study 2: Number of Participants with Clinical Remission at Week 4
Clinical remission is defined as CDAI score\< 150.
Time frame At Week 4
Secondary outcome
Induction Study 2: Number of Participants Reporting Both Histologic Remission and Endoscopic Remission at Week 12
Histologic remission is defined as a Robarts Histopathology Index score \<=3, where each of the items of lamina propria neutrophils, neutrophils in epithelium, and erosions or ulcerations must be equal to 0. Endoscopic remission is defined as SES-CD \<= 4 with at least a 2-point reduction from baseline and no sub score \>1 in any individual component. This is a composite endpoint defined as achieving both histologic remission and endoscopic remission at the participant level.
Time frame At Week 12
Secondary outcome
Induction Study 2: Number of Participants with AEs and SAEs
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. An SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important.
Time frame Up to 4 weeks after last dose of study drug (i.e., up to Week 16)
Secondary outcome
Maintenance Study: Number of Participants with PRO-2 remission at Week 40
PRO-2 remission is defined as an abdominal pain (AP) mean daily score \<= 1 and stool frequency (SF) mean daily score \<= 2.8, and no worsening of AP or SF from baseline.
Time frame At Week 40
Secondary outcome
Maintenance Study: Number of Participants with Endoscopic Remission at Week 40
Endoscopic remission is defined as SES-CD \<= 4 with at least a 2-point reduction from baseline and no sub score \>1 in any individual component.
Time frame At Week 40
Secondary outcome
Maintenance Study: Number of Participants with 90-Day Corticosteroid-Free Clinical Remission at Week 40
90-day corticosteroid-free clinical remission is defined as the clinical remission at the visit and not receiving corticosteroids for at least 90 days prior to the visit. Clinical remission is defined as CDAI score \< 150.
Time frame At Week 40
Secondary outcome
Maintenance Study: Number of Participants with Maintenance of Clinical Remission at Week 40
Participants with clinical remission at Week 40 among those with clinical remission at Week 0 of the maintenance study will be analyzed. Clinical remission is defined as CDAI score \< 150.
Time frame At Week 40
Secondary outcome
Maintenance Study: Number of Participants Reporting Both Clinical Remission and Endoscopic Response at Week 40
Clinical remission is defined as CDAI score \< 150. Endoscopic response is defined as \> 50% improvement from baseline in SES-CD score or a decrease of at least 2 points in participants with a baseline score of 4 and isolated ileal disease. This is a composite endpoint defined to measure achievement of both clinical remission and endoscopic response at the participant level.
Time frame At Week 40
Secondary outcome
Maintenance Study: Number of Participants with Deep Remission at Week 40
Deep remission is a composite endpoint defined as achieving both clinical remission and endoscopic remission at the participant level. Clinical remission is defined as CDAI score \< 150. Endoscopic remission is defined as SES-CD \<= 4 with at least a 2-point reduction from baseline and no sub score \>1 in any individual component.
Time frame At Week 40
Secondary outcome
Maintenance Study: Number of Participants Reporting Both Histologic Remission and Endoscopic Remission at Week 40
Histologic remission is defined as a Robarts Histopathology Index score \<=3, where each of the items of lamina propria neutrophils, neutrophils in epithelium, and erosions or ulcerations must be equal to 0. Endoscopic remission is defined as SES-CD \<= 4 with at least a 2-point reduction from baseline and no sub score \>1 in any individual component. This is a composite endpoint defined as achieving both histologic remission and endoscopic remission at the participant level.
Time frame At Week 40
Secondary outcome
Maintenance Study: Number of Participants with IBDQ Remission at Week 40
IBDQ remission is defined as IBDQ score \>= 170. IBDQ is a validated, 32-item, self-reported questionnaire for participants with IBD that will be used to evaluate the disease-specific HRQoL across 4 dimensional scores: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Scores range from 32 to 224, with higher scores indicating better outcomes.
Time frame At Week 40
Secondary outcome
Maintenance Study: Number of Participants with Fatigue Response at Week 40
Fatigue response is defined as a \>= 7 point reduction in the PROMIS-Fatigue Short Form 7a total score from baseline. The PROMIS fatigue SF-7a contains 7 items evaluating fatigue-related symptoms (that is, tiredness, exhaustion, mental tiredness, and lack of energy) and associated impacts on daily activities (that is, activity limitations related to work, self-care, and exercise). Item responses are rated on a five-point scale ranging from "never" to "always". Higher scores indicate more fatigue.
Time frame At Week 40
Secondary outcome
Maintenance Study : Number of Participants with AEs and SAEs
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. An SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important.
Time frame Up to 4 weeks after last dose of study drug (i.e., up to Week 44)

Dates

Dates
Start date	October 3, 2025 (actual)
Primary completion	September 19, 2028 (estimated)
Completion	October 10, 2032 (estimated)
First posted	September 29, 2025 (actual)
Last updated	August 28, 2026
Results posted	Not stated in the registry record
Status last verified	August 2026

Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.

Locations

361 sites are recruiting

Argentina

Argentina
Facility	City	Status
GEDYT	AAI	Recruiting
Hospital Aleman	Buenos Aires	Recruiting
Hospital Britanico de Buenos Aires	CABA	Recruiting
Clinica Universitaria Reina Fabiola	Córdoba	Recruiting
Hospital Privado de Cordoba	Córdoba	Recruiting
Sanatorio Maipu	Maipu	Recruiting
HIGEA	Mendoza	Recruiting

Australia

Australia
Facility	City	Status
Monash Health	Clayton	Recruiting
Concord Repatriation General Hospital	Concord	Recruiting
St Vincents Hospital Melbourne	Fitzroy	Recruiting
Fiona Stanley Hospital	Murdoch	Recruiting
John Hunter Hospital	New Lambton Heights	Recruiting
Mater Hospital Brisbane	South Brisbane	Recruiting

Belgium

Belgium
Facility	City	Status
Cliniques Universitaires Saint Luc	Brussels	Recruiting
CHU Saint-Pierre	Brussels	Recruiting
AZ St. Lucas	Ghent	Recruiting
Ghent University Hospital	Ghent	Recruiting
Universitair Ziekenhuis Leuven	Leuven	Recruiting
Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman	Liège	Recruiting
AZ Oostende	Ostend	Recruiting
CHwapi	Tournai	Recruiting

Brazil

Brazil
Facility	City	Status
Faculdade de Medicina Universidade Federal de Minas Gerais	Belo Horizonte	Recruiting
UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu	Botucatu	Recruiting
Chronos Clinica Medica Ltda	Brasília	Recruiting
L2IP Instituto de Pesquisas Clinicas	Brasília	Recruiting
CDC - Centro Digestivo de Curitiba	Curitiba	Recruiting
ATO Terapias	Fortaleza	Recruiting
CECIP Jau - Centro de Estudos Clínicos do Interior Paulista Ltda	Jaú	Recruiting
Galileo Medical Research Ltda	Juiz de Fora	Recruiting
Cliged	Macaé	Recruiting
Liga Norte Riograndense Contra O Cancer	Natal	Recruiting
Complexo Hospitalar de Niteroi	Niterói	Recruiting
Hospital De Clinicas De Porto Alegre	Porto Alegre	Recruiting
Hospital Ernesto Dornelles	Porto Alegre	Recruiting
Hospital Moinhos de Vento	Porto Alegre	Recruiting
Platano Centro De Pesquisa Clinica LTDA	Recife	Recruiting
Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto	Ribeirão Preto	Recruiting
Clinica Ibis Medicina Ltda	Salvador	Recruiting
Pesquisare Saude	Santo André	Recruiting
Irmandade da Santa Casa da Misericórdia de Santos	Santos	Recruiting
Funfarme Sjrp	São José do Rio Preto	Recruiting
Hospital Santa Catarina	São Paulo	Recruiting
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein	São Paulo	Recruiting
Hospital Das Clinicas Da Faculdade De Medicina Da USP	São Paulo	Recruiting
Solare Trials	São Paulo	Recruiting
BR Trials	São Paulo	Recruiting
INTEGRAL Pesquisa e Ensino	Votuporanga	Recruiting

Canada

Canada
Facility	City	State or region	Status
Barrie GI Associates	Barrie	Ontario	Recruiting
South Edmonton Gastroenterology Research Clinic	Edmonton	Alberta	Recruiting
Viable Clinical Research	Kentville	Nova Scotia	Recruiting

320 further sites are listed in the registry record.

Study documents

No documents are linked in this registry record.

Changes over time

August 28, 2026
Site added
2 sites added (370 total)
368370
July 31, 2026
Site added
1 site added (368 total)
367368

Registry: ClinicalTrials.gov · NCT########

https://xmedica.io/trials/ctgov/NCT07196722

Categories

Registered in 1 registry

Interested in this study?

How this study is set up

Summary

Conditions

Eligibility

Eligibility as written in the registry

Eligibility in plain statements

Study design

Sponsor and collaborators

Arms and interventions

Interventions

Outcome measures

Dates

Locations

Argentina

Australia

Belgium

Brazil

Canada

Study documents

Changes over time